Enhancer of zeste homolog 2 (EZH2), an essential catalytic subunit of the polycomb 2 repressive complex (PRC2), has been reported to be associated with OSCC carcinogenesis and adverse outcomes in patients with oral cancer [6,7]. This evidence concerns the gene EZH2 and lip and oral cavity carcinoma.